CHATTANOOGA, TN--(Marketwired - Jun 23, 2015) - The Occlusion Perfusion Catheter™ (OPC), a FDA-approved multi-lumen balloon catheter providing targeted intravascular drug delivery, was featured in a live case presentation during the 16th Annual New Cardiovascular Horizons (NCVH) Conference. Frank T. Bunch, M.D., F.A.C.C., principal investigator for the COPPER-A clinical trial, performed the case, which can be viewed on the NCVH website at 1:50 PM. Dr. Bunch also made a presentation on the science behind the OPC at the conference.

Rex Teeslink, M.D., the device's inventor, NCVH faculty member, and scientific advisor for Advanced Catheter Therapies, Inc. (ACT), was present for the live case, something that both he and Dr. Bunch pointed to as a milestone for the device. "It was very exciting to be part of a live case," said Dr. Teeslink. "It shows attendees that science is progressing beyond drug coated balloons. We believe the OPC represents the next generation of drug delivery devices."

The clinical trial for the OPC is being conducted by the Horizons International Peripheral Group (HIPG), a membership based organization comprised of the leading innovators, educators, researchers and advocates for the advancement of the diagnosis and management of patients with Peripheral Vascular Disease (PVD). COPPER-A is focused on the prevention of restenosis above the knee in the superficial femoral and popliteal arteries, and COPPER-B is also a clinical trial conducted by HIPG for the prevention of restenosis below the knee.

"Thus far, we have enrolled three patients in COPPER-A and five in COPPER-B; four of the COPPER-B patients have had 30-day follow-ups, and we received positive results on all endpoints," said Dr. Bunch, who is with Cardiology Associates in Mobile, AL. "COPPER-A is a multi-center, prospective, non-randomized controlled trial that will enroll 150 patients in up to 10 sites in the U.S. Site selection is progressing as we review patient volume and each center's ability to meet our inclusion/exclusion criteria."

The OPC is a multi‐lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the targeted delivery of various therapeutic and diagnostic agents to the peripheral vasculature. The OPC, which is disease and agent agnostic, has the ability to create a localized treatment chamber and place the agent circumferentially and longitudinally into the vessel wall. Inflow and outflow ports allow for chamber evacuation, filling and flushing.

The OPC is unique in being able to measure pressure applied inside the treatment chamber. It affords clinicians substantial procedural control along with the ability to select the agent and volume, as well as preventing systemic release of the agent.

About ACT
Advanced Catheter Therapies, Inc., a research and development medical device company, has a portfolio of innovative catheter technologies targeting vascular disease including thrombosis, inflammation, occlusions and restenosis.

Contact Information:

ACT contact:
Mark Rich


Media inquiries:
Lynn Hood